ClinicalTrials.gg
CompletedNCT05062759VECTORUpdated Jun 22, 2023Results posted

Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

A Phase 3 interventional study of Tezepelumab and Placebo in Moderate to Severe Asthma, sponsored by AstraZeneca. Completed at 15 sites in United States. Open to participants aged 12 Years to 21 Years. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
12 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
18th of 28
70 · median 121
Started
2021
with 1 other
Phase 3
16 of 28
4 open now
Registered
14th of 28
by date
Lead sponsor
16 of 28
AstraZeneca

Among the 28 studies testing tezepelumab in Asthma, this one is the 18th largest by enrollment, is one of 2 that started in 2021, is one of 16 in phase 3, and was the 14th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous [SC] every 4 weeks [Q4W]) on antibody responses following seasonal quadrivalent influenza virus vaccination in the fall/winter 2021-2022 in the USA.

Read the detailed description

Participants with moderate to severe asthma will enter the screening period of a minimum of 2 weeks to allow adequate time for all of the eligibility criteria to be evaluated. They will be randomized 1:1 to receive tezepelumab 210 mg or placebo SC Q4W, administered at Weeks 0, 4, 8 and 12. Randomization will be monitored to ensure at least 50% of the randomized participants are between the ages of 12 to 17 years.

Participants will receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.

Serum samples for evaluation of antibody response will be drawn at Week 12 (pre-vaccination) and at Week 16 (4 weeks post-vaccination) when humoral response to the vaccination is expected to be fully developed.

The End of Treatment (EOT) Visit will be conducted at Week 16 and a final Follow-up Visit and the End of Study Visit will be conducted at Week 28.

03

Conditions studied

  • Moderate to Severe Asthma

Browse trials for

Keywords

  • Tezepelumab
  • Humoral Immune Response
  • Quadrivalent Influenza Vaccination
  • Antibody response
  • Subcutaneous
04

Who can participate

Ages eligible
12 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented physician-diagnosed asthma for at least 12 months prior to Visit 1.
  • Morning pre-bronchodilator (Forced expiratory volume) of > 50% predicted normal value at Visit 1 or Visit 2.
  • Body weight ≥ 40 kg.
  • For women of , a negative urine pregnancy test is required prior to administration of study intervention at Visit 3.
  • Must have 'not well-controlled' asthma.

Exclusion criteria

Exclusion Criteria:

  • pulmonary disease other than asthma.
  • Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment.
  • Life-threatening asthma
  • History of cancer.
  • Allergy to eggs, if egg based influenza vaccine will be administered.
  • History of anaphylaxis to any biologic therapy.
  • Current smokers or participants with smoking history ≥ 10 pack-years and participants using vaping products, including electronic cigarettes. Former smokers with a smoking history of \< 10 pack-years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible.
  • History of alcohol or drug abuse within 12 months prior to the date of .
  • Major surgery within 8 weeks prior to Visit 1 or planned surgical procedures during the conduct of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Tezepelumab

    Participants will be randomized to receive tezepelumab 210 mg administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.

    Drug: Tezepelumab

  • Placebo comparator
    Placebo to Tezepelumab

    Participants will be randomized to receive placebo SC Q4W, administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.

    Drug: Placebo

Interventions

  • 210 mg SC injection Q4W.

  • DrugPlacebo

    SC injection Q4W.

06

What researchers measure

Primary outcomes

  1. Post-vaccination Strain-specific Hemagglutination Inhibition (HAI) Antibody Geometric Mean Fold Rises (GMFRs)

    Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.

    Time frame: From Week 12 to Week 16

  2. Post-vaccination Strain-specific Microneutralization (MN) Antibody GMFRs

    Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.

    Time frame: From Week 12 to Week 16

  3. Post-vaccination Strain-specific Serum HAI Antibody Geometric Mean Titers (GMTs)

    Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.

    Time frame: Week 16

  4. Post-vaccination Strain-specific Serum MN Antibody GMTs

    Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.

    Time frame: Week 16

  5. Percentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in HAI Antibody Titer

    Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.

    Time frame: Week 16

  6. Percentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in MN Antibody Titer

    Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. Vaccine immunogenicity analysis set consisted of all randomised patients who received the influenza vaccine plus at least 1 dose of tezepelumab or placebo, had pre and post vaccination HAI or MN antibody measurements, had no influenza infection prior to Visit 7 (Week 16), and had no protocol deviation, judged to have the potential to interfere with the generation or interpretation of an antibody response.

    Time frame: Week 16

  7. Percentage of Patients With Post-vaccination Strain-specific HAI Antibody Titer ≥ 40

    Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.

    Time frame: Week 16

  8. Percentage of Patients With Post-vaccination Strain-specific MN Antibody Titer ≥ 40

    Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.

    Time frame: Week 16

Secondary outcomes

  1. Serum Tezepelumab Concentrations

    Tezepelumab serum concentrations were summarized using descriptive statistics at each visit.

    Time frame: Week 0, Week 12, Week 16 and Week 28

  2. Immunogenicity

    Immunogenicity assessments were performed. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.

    Time frame: From Baseline to Week 28

07

Results

Posted Apr 21, 2023

Participant flow

This study was conducted in 15 study centres in the United States between 23 August 2021 and 18 July 2022.

Participant flow — Overall Study
MilestoneTezepelumabPlacebo
Started3535
Completed3434
Not completed11
Withdrew: Death01
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPost-vaccination Strain-specific Hemagglutination Inhibition (HAI) Antibody Geometric Mean Fold Rises (GMFRs)

Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.

Time frame:
From Week 12 to Week 16
Reported as:
Geometric mean · Fold change
Post-vaccination Strain-specific Hemagglutination Inhibition (HAI) Antibody Geometric Mean Fold Rises (GMFRs)
Fold changeTezepelumabPlacebo
Influenza A H1N17.34 ± 1.3614.75 ± 1.455
Influenza B Yamagata Lineage1.76 ± 0.9551.46 ± 0.937
Influenza B Victoria Lineage2.94 ± 1.0542.90 ± 0.841
Statistical analysis
  • Tezepelumab vs Placebo · Geometric least square (ls) mean ratio: 0.65 · 90% CI 0.43 to 0.98
  • Tezepelumab vs Placebo · Geometeric ls mean ratio: 0.83 · 90% CI 0.60 to 1.15
  • Tezepelumab vs Placebo · Geometric ls mean ratio: 0.99 · 90% CI 0.71 to 1.37
PrimaryPost-vaccination Strain-specific Microneutralization (MN) Antibody GMFRs

Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.

Time frame:
From Week 12 to Week 16
Reported as:
Geometric mean · Fold change
Post-vaccination Strain-specific Microneutralization (MN) Antibody GMFRs
Fold changeTezepelumabPlacebo
Influenza A H1N114.56 ± 2.58110.62 ± 2.409
Influenza A H3N24.73 ± 1.5095.90 ± 3.180
Influenza B Yamagata Lineage4.00 ± 1.5413.56 ± 2.206
Influenza B Victoria Lineage4.08 ± 2.2795.04 ± 1.723
Statistical analysis
  • Tezepelumab vs Placebo · Geometeric ls mean ratio: 0.73 · 90% CI 0.42 to 1.28
  • Tezepelumab vs Placebo · Geometeric ls mean ratio: 1.25 · 90% CI 0.72 to 2.17
  • Tezepelumab vs Placebo · Geometric ls mean ratio: 1.23 · 90% CI 0.73 to 2.07
  • Tezepelumab vs Placebo · Geometeric ls mean ratio: 0.89 · 90% CI 0.54 to 1.48
PrimaryPost-vaccination Strain-specific Serum HAI Antibody Geometric Mean Titers (GMTs)

Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.

Time frame:
Week 16
Reported as:
Geometric mean · Titer
Post-vaccination Strain-specific Serum HAI Antibody Geometric Mean Titers (GMTs)
TiterTezepelumabPlacebo
Influenza A H1N1809.23 ± 0.921596.76 ± 1.076
Influenza B Yamagata Lineage167.46 ± 0.925161.56 ± 0.688
Influenza B Victoria Lineage194.68 ± 1.089200.55 ± 0.948
Statistical analysis
  • Tezepelumab vs Placebo · Geometeric ls mean ratio: 0.74 · 90% CI 0.52 to 1.04
  • Tezepelumab vs Placebo · Geometeric ls mean ratio: 0.96 · 90% CI 0.72 to 1.29
  • Tezepelumab vs Placebo · Geometric ls mean ratio: 1.03 · 90% CI 0.73 to 1.46
PrimaryPost-vaccination Strain-specific Serum MN Antibody GMTs

Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.

Time frame:
Week 16
Reported as:
Geometric mean · Titer
Post-vaccination Strain-specific Serum MN Antibody GMTs
TiterTezepelumabPlacebo
Influenza A H1N1382.55 ± 1.469303.63 ± 1.667
Influenza A H3N2600.92 ± 2.154457.33 ± 2.336
Influenza B Yamagata Lineage355.44 ± 1.076366.81 ± 1.270
Influenza B Victoria Lineage125.67 ± 4.687124.35 ± 3.515
Statistical analysis
  • Tezepelumab vs Placebo · Geometeric ls mean ratio: 0.79 · 90% CI 0.51 to 1.25
  • Tezepelumab vs Placebo · Geometeric ls mean ratio: 0.76 · 90% CI 0.42 to 1.28
  • Tezepelumab vs Placebo · Geometric ls mean ratio: 0.99 · 90% CI 0.49 to 1.99
  • Tezepelumab vs Placebo · Geometeric ls mean ratio: 1.03 · 90% CI 0.70 to 1.52
PrimaryPercentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in HAI Antibody Titer

Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in HAI Antibody Titer
Percentage of participantsTezepelumabPlacebo
Influenza A H1N178.8 ± 63.8251.5 ± 36.07
Influenza B Yamagata Lineage15.2 ± 6.1715.2 ± 6.17
Influenza B Victoria Lineage30.3 ± 17.4639.4 ± 25.11
PrimaryPercentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in MN Antibody Titer

Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. Vaccine immunogenicity analysis set consisted of all randomised patients who received the influenza vaccine plus at least 1 dose of tezepelumab or placebo, had pre and post vaccination HAI or MN antibody measurements, had no influenza infection prior to Visit 7 (Week 16), and had no protocol deviation, judged to have the potential to interfere with the generation or interpretation of an antibody response.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in MN Antibody Titer
Percentage of participantsTezepelumabPlacebo
Influenza A H1N181.8 ± 67.2475.8 ± 60.49
Influenza A H3N260.6 ± 44.8251.5 ± 36.07
Influenza B Yamagata Lineage51.5 ± 36.0736.4 ± 22.50
Influenza B Victoria Lineage54.5 ± 38.9463.6 ± 47.84
PrimaryPercentage of Patients With Post-vaccination Strain-specific HAI Antibody Titer ≥ 40

Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Patients With Post-vaccination Strain-specific HAI Antibody Titer ≥ 40
Percentage of participantsTezepelumabPlacebo
Influenza A H1N1100 ± 91.32100 ± 91.32
Influenza B Yamagata Lineage97 ± 86.41100 ± 91.32
Influenza B Victoria Lineage100 ± 91.3297.0 ± 86.41
PrimaryPercentage of Patients With Post-vaccination Strain-specific MN Antibody Titer ≥ 40

Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Patients With Post-vaccination Strain-specific MN Antibody Titer ≥ 40
Percentage of participantsTezepelumabPlacebo
Influenza A H1N1100 ± 91.3293.9 ± 82.13
Influenza A H3N293.9 ± 82.1397 ± 86.41
Influenza B Yamagata Lineage97 ± 86.41100 ± 91.32
Influenza B Victoria Lineage78.8 ± 63.8281.8 ± 67.24
SecondarySerum Tezepelumab Concentrations

Tezepelumab serum concentrations were summarized using descriptive statistics at each visit.

Time frame:
Week 0, Week 12, Week 16 and Week 28
Reported as:
Geometric mean · microgram/milliliter (μg/mL)
Serum Tezepelumab Concentrations
microgram/milliliter (μg/mL)Tezepelumab
Week 0NA ± NA
Week 1227.00 ± 0.5421
Week 1620.76 ± 3.6969
Week 282.79 ± 1.0705
SecondaryImmunogenicity

Immunogenicity assessments were performed. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.

Time frame:
From Baseline to Week 28
Reported as:
Number · Patients
Immunogenicity
PatientsTezepelumabPlacebo
ADA prevalence04
Only baseline ADA positive00
Both baseline and post-baseline ADA positive00
Any baseline ADA positive00
Any post-baseline ADA positive04
Treatment-induced ADA positive04
ADA persistently positive04
ADA transiently positive00
Treatment-boosted ADA positive00
TE-ADA positive (ADA incidence)04

Adverse events

Collected over From the date of the first dose of study drug, throughout the treatment period up to the follow-up period or end of the study visit (Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tezepelumab0/35 (0%)0/35 (0%)14/35 (40%)
Placebo1/35 (2.9%)1/35 (2.9%)15/35 (42.9%)
Most frequent serious events
Most frequent serious events
EventTezepelumabPlacebo
Stab woundInjury, poisoning and procedural complications0/351/35
Most frequent other events
Most frequent other events
EventTezepelumabPlacebo
COVID-19Infections and infestations8/358/35
Acute sinusitisInfections and infestations3/350/35
Ear infectionInfections and infestations1/352/35
Viral upper respiratory tract infectionInfections and infestations1/352/35
PharyngitisInfections and infestations0/352/35
SinusitisInfections and infestations0/352/35
ArthralgiaMusculoskeletal and connective tissue disorders1/352/35
Skin lacerationInjury, poisoning and procedural complications2/350/35

Baseline characteristics

All patients randomised and receiving any study intervention were included in the Full analysis set, irrespective of their CSP adherence and continued participation in the study.

Age, Continuous
Age, Continuous(years)TezepelumabPlaceboTotal
Mean16.3 ± 2.316.6 ± 3.116.5 ± 3.0
Age, Customized
Age, Customized(Participants)TezepelumabPlaceboTotal
In utero000
Preterm newborn infants (gestational age < 37 wks)000
Newborns (0-27 days)000
Infants and toddlers (28 days-23 months)000
Children (2-11 years)000
Adolescents (12-17 years)222143
Adults (18-64 years)131427
From 65-84 years000
85 years and over000
Sex: Female, Male
Sex: Female, Male(Participants)TezepelumabPlaceboTotal
Female141125
Male212445
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TezepelumabPlaceboTotal
Hispanic or Latino81018
Not Hispanic or Latino272552
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TezepelumabPlaceboTotal
White242347
Black or African American81220
Asian101
American Indian or Alaska Native202
08

Study locations

15 sites
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Huntington Beach, California 92647, United States
  • Research Site
    Miami, Florida 33133, United States
  • Research Site
    Columbia, Missouri 65203, United States
  • Research Site
    Northfield, New Jersey 08225, United States
  • Research Site
    Dayton, Ohio 45406, United States
  • Research Site
    Toledo, Ohio 43617, United States
  • Research Site
    Edmond, Oklahoma 73034, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Dallas, Texas 75225, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Tyler, Texas 75708, United States
  • Research Site
    Waco, Texas 76712, United States
  • Research Site
    Salt Lake City, Utah 84107, United States
  • Research Site
    Milwaukee, Wisconsin 53228, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Mar 2022, 6 months.

Results were first posted in Apr 2023, 1 year 1 month after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 6 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2021
First posted
Sep 30, 2021
StartActual
Aug 23, 2021
Primary completionActual
Mar 21, 2022
CompletionActual
Jul 18, 2022
Results first posted
Apr 21, 2023
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05062759
Lead sponsor
AstraZeneca
Collaborators
Amgen
Responsible party
Sponsor
First posted
Sep 30, 2021
Start date
Aug 23, 2021
Primary completion
Mar 21, 2022
Completion
Jul 18, 2022
Results posted
Apr 21, 2023
Last update
Jun 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion